Close menu




December 3rd, 2020 | 11:51 CET

Bayer, Carnival, Silver Viper - Rough weather on the high seas!

  • Investments
Photo credits: Silver Viper Minerals

Gold up 60 Dollars! Precious metals are beginning to recover from their recent decline in the options market. It is often rumored that the sales in gold & silver have to do with raising money from the prominent market players. Short Gold - Long Nasdaq. The NDX, in any case, climbed to a new all-time high yesterday. In the face of renewed speculation frenzy, which also drove the Bitcoin price back to record highs, some financial media have revived the old argument. The Blockchain creature would be the new gold is the slogan, but some Tweets also show, e.g., from market analyst Fred Hickey, why Bitcoin should not be confused with the yellow metal: "The history of gold is 3,000 years old - that of Bitcoin not even 10 - and gold has a natural attraction!" Currently, the value ratio is 10:1 - Gold analysts see the price at over USD 20,000 in 2025, but Bitcoin already costs that today.

time to read: 4 minutes | Author: André Will-Laudien
ISIN: CA8283341029 , GB0031215220 , DE000BAY0017

Table of contents:


    Bayer - The naughty daughter

    A federal judge has rejected Bayer AG's proposed USD 648 million settlement in a class-action lawsuit filed by cities and other plaintiffs alleging PCB contamination. In a decision issued on November 25, the US District Judge in Los Angeles said the agreement appeared "too broad in scope" because it could shield Bayer from future claims and would require the plaintiffs to indemnify Bayer against such claims. Bayer acquired Monsanto for USD 63 billion in 2018 and said in a statement that it would work with plaintiffs to resolve their concerns. Los Angeles County and the cities of San Diego, Baltimore and Portland are among the plaintiffs, who are now from 36 states. The payout was to include USD 550 million for Class Members and up to USD 98 million for attorneys' fees and disbursements. For the time being, the proceedings continue.

    Already in June, Bayer announced plans to pay approximately USD12 billion to settle litigation relating to Monsanto's herbicide Roundup. Bayer has now stated that Roundup is safe and well-tolerated by humans. A further problem exists with polychlorinated biphenyls (PCBs). They were once used extensively to insulate electrical appliances and were also used in products such as carbonless paper, sealants, flooring and paints. The US government banned PCBs in 1979 after they were linked to cancer and other health problems. Monsanto produced PCBs from 1935 to 1977, and now the Company is trying to close the story once and for all.

    Bayer is still swirling in the US wave of lawsuits, and in 2020, is one of the weakest stocks in the DAX. The Company has a market value of only about EUR 47 billion, at its height, it used to be over EUR 130 billion. When Bayer will be able to escape from the clutches of justice remains questionable. In any case, the Monsanto takeover will go down in the history books as one of the most significant value destructions of all time. For Bayer, this is a disservice done by a management team that is completely detached from the Company.

    Carnival Corp. - Goodbye cruises

    The recent explosion of coronavirus infections means the expectation that cruises will commence are premature. Carnival, together with Royal Caribbean and Norwegian Cruise Lines, is one of the big 3 players in this sector, which has been lying idle since the beginning of the year. The pre-sold cruises for February and March are cancelled again. One can now only hope for free travel in the summer.

    The stocks of the badly shaken industry crashed again. Carnival's annual loss amounts to an impressive 60%. The share recovered by 60% from its November low, but the volatility demonstrates the pitfall of the percentage calculation. The long term investor is sitting on massive losses, the short term oriented and courageous speculator, armed with the hope of a vaccine, can calmly realize again and hope for the next sell-off of the stock. Fundamentally, all significant lines are already on the verge of over-indebtedness, and various government aid packages have been applied for.

    Given the 99 percent drop in sales, the third quarter was an absolute catastrophe, and the figures for the fourth quarter could hardly be better. The fiscal year ended now on November 30, and Carnival will probably report the worst figures in its long history. However, the stock market threw out a lifebelt, as Carnival reported a sale of shares worth USD 1.5 billion on November 10. They took advantage of the rally after the US election, in which the shares rose from USD 14 to over USD 20.

    The new money will now delay the risk of bankruptcy, but not for too long. Only on the assumption of rapid global approval of a vaccine and a quick market launch could the tide turn; otherwise, the pandemic will continue well into 2021. That may be too long for Carnival. Management sold shares yesterday after reaching a 6-month high.

    Silver Viper - First-class projects, tax effects

    "Tax Loss Selling" is the keyword of the last days. In the course of the somewhat lighter precious metal prices, many mines and explorers also went down. Canadian investors are taking advantage of the tax benefits to offset their annual profits with incurred losses, in turn creating liquidity resources for re-entry after the turn of the year. The promising Silver Viper also entered the correction mill with a 50 percent loss - but the projects are still 1A in character.

    The former Pan American Silver project "La Virginia" not only has first-class historical exploration, but the drill bit has recently uncovered discoveries and great potential in new zones such as El Rubi. The gold-silver project is located in northern Sonora, the leading gold-producing state of Mexico.

    With a total of 188 drill holes and peak values of 7.63 grams of gold and 363 grams of silver per tonne, the area is truly inspiring as the structures are relatively near surface. Much of the project has not yet been mapped or drilled, which certainly offers some surprises. As of September 30, the balance sheet carried USD 4.3 million in cash, enough to continue into the new year, as Silver Viper currently has an excellent track record of discoveries at La Virginia and the new El Rubi zone.

    Management and institutional investors own 83% of the shares, leaving only a small free float of 17%. Nearly halved in value since the summer, the Company has a capitalization of only CAD 36 million. It should therefore come as no surprise that after the tax-induced sales, a stronger catch-up movement is starting in December.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author



    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read

    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.

    Read

    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?

    Read